HUNTSVILLE — Discovery Life Sciences, a Huntsville-based biospecimen solutions and specialty lab services company, will launch a product to help advance oncology research.
Tumoroid Cell Lines, OncoPro Medium-Derived will be introduced March 11-13 at Precision Med Tri-Con 2025 in San Diego.
“Our tumoroid cell lines are a transformative tool that can help eliminate major barriers to oncology research, giving scientists a powerful, predictive tool to identify life-changing therapies faster,” said McLean Collins, Discovery’s president of Biospecimens Products & Services. “This product also represents Discovery’s continued commitment to driving innovation in cancer research and complements our cell biology offerings in CFC and ADC assays along with our 10X single cell portfolio.”
Tumoroid Cell Lines, OncoPro Medium-Derived are patient-derived cancer cells that are cultivated as 3D, self-organized multicellular structures, serving as highly predictive tools for drug and diagnostic development and offering greater biological relevance compared to traditional 2D cancer models.
“We will be showcasing several exciting studies at Precision Med Tri-Con this year, highlighting our dedication to advancing precision medicine by integrating advanced technologies and high-quality biospecimens into our workflows,” said Dr. Shawn Fahl, vice president, Lab Operations, Cell Services & R&D, Biospecimens. “We look forward to engaging with the scientific community and exploring new ways to shape the future of oncology research together.”
Discovery’s strategic investments in advanced technologies, including AI-powered pathology and retrospective clinical biomarker testing workflows, empower its customers with actionable, quantitative insights from biospecimens. For more information about Discovery’s products and services, visit www.dls.com.
